FDA gives nod to first once-daily protease inhibitor
A protease inhibitor (PI) that circumvents the problems of earlier PIs such as certain adverse events, a complex dosing regimen, and toxicities such as lipid disturbances and glucose metabolism will soon be available to those infected with HIV. The FDA recently approved atazanavir (Reyataz, Bristol-Myers Squibb) for use in combination with other antiretroviral agents for the treatment of HIV infection. Atazanavir will be available in pharmacies sometime this month.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Related Content
